Eli Lilly Acquires Calytrix Bio for Up to $1.5 Billion
Eli Lilly acquired biotechnology startup Calytrix Bio to advance a biparatopic antibody treatment for rare blood cancers.
Eli Lilly and Company acquired Calytrix Bio, a Massachusetts-based biotechnology startup, for a total potential payment of $1.5 billion. The deal structure consists of an upfront payment followed by subsequent payouts tied to the achievement of clinical and regulatory milestones.
Calytrix Bio specializes in treatments for rare blood cancers, specifically developing a biparatopic antibody that targets the CALR gene mutation. This therapy is designed for patients with myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. The goal of the program is to alter the trajectory of the disease rather than simply managing symptoms.
This acquisition is part of a broader expansion strategy for Eli Lilly, which has emerged as the most prolific dealmaker in the biotech sector in 2026. The company has spent over $30 billion on 15 different company acquisitions throughout the year.